AbbVie Inc. is 353.5x more valuable than Zenas BioPharma, Inc. by market capitalization ($399.47 B vs $1.13 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ZBIO | ABBV |
|---|---|---|
| Market cap | $1.13 B | $399.47 B |
| US-listed rank | #2546 | #28 |
| Revenue (latest FY) | $10.00M | $61.16B |
| Net income (latest FY) | -$377.74M | $4.23B |
| Net margin | -3777.4% | 6.9% |
| P/E (trailing FY) | - | 94.5 |
| SEC filings | 166 | 1,008 |
AbbVie Inc. is 353.5x more valuable than Zenas BioPharma, Inc. by market capitalization ($399.47 B vs $1.13 B).
In their latest fiscal years, Zenas BioPharma, Inc. reported $10.00M in revenue while AbbVie Inc. reported $61.16B.
Full pages: Zenas BioPharma, Inc. and AbbVie Inc., or browse the full rankings.